期刊文献+

乳头状肾癌的诊治(附32例报告及文献复习) 被引量:1

The diagnosis and treatment of papillary renal carcinoma (Report of 32cases and review)
原文传递
导出
摘要 目的:提高乳头状肾癌的诊治水平。方法:回顾性分析32例乳头状肾癌患者的临床资料。28例行开放性根治性肾切除术,3例行后腹腔镜下根治性肾切除术,1例行后腹腔镜下肾部分切除。结果:术后病理均为乳头状肾癌。采用2002年AJCC肾癌TNM病理分期:pT1aN0M04例,pT1bN0M014例,pT2aN0M010例,pT2bN0M01例,pT2bN1M01例,pT3aN0M02例,病理分级:G121例,G210例,G31例。28例获16~30个月随访,平均20个月,2例死于心脏病,3例死于脑血管意外,1例局部复发,22例无瘤生存。结论:乳头状肾癌是一种具有特殊形态和表现的少见肾癌类型,部分肾切除及根治性肾切除术是治疗乳头状肾癌的首选方法,与其他类型肾细胞癌相比,乳头状肾癌预后较好。 Objective:Improve the diagnosis and treatment of papillary renal carcinoma. Method:The clinical data of 32 patients with papillary renal carcinoma were analyzed retrospectively. 28 patients were treated with radical nephrectomy, 3 of which were treated by laparoseopic nephrectomy. 1 patient was treated with laparoscopic partial nephrectomy. Result:Post-operation pathology confirm that all the specimen were papillary renal carcinoma, pathology stage (2002 AJCC renal carcinoma TNM pathology stage) : pT1oNoMo4 cases, pT1oNoMo14 cases, pT2b NoMo10 cases, pT2bNoMo 1 case, p2bTN1Mo 1 case, pT3aNoMo 2 cases, pathology grade: G1 21 cases, G2 10 cases, G3 1 case. 28 patients were followed-up for 16-30 months, mean 20 months. 2 patients died of heart Disease, 3 patients died of cerebrovascular accident, 1 patient suffered from local recurrence, 22 patients tumor-free survive. Conclusion:Papillary renal carcinoma is a kind of rare renal carcinoma with special morphous and characteristic. Radical nephrectomy and partial nephrectomy is the first choice treatment of papillary renal carcinoma. Compared with other kinds of renal carcinoma, it has a better prognosis.
出处 《临床泌尿外科杂志》 2013年第5期332-333,336,共3页 Journal of Clinical Urology
关键词 乳头状肾癌 诊断 治疗 papillary renal carcinoma diagnosis treatment
  • 相关文献

参考文献6

  • 1谢文虎,孙光,刘晓强,刘雨,王一.乳头状肾癌的临床与病理分析(附24例报道)[J].天津医科大学学报,2008,14(4):552-554. 被引量:7
  • 2Zhang C, Li X,Hao H,et al. The correlation betweensize of renal cell carcinoma and its histopathologicalcharacteristics: a single center study of 1867 renal cellcarcinoma cases [J]. BJU Int, 2012,110 : E481 —E485.
  • 3Ignee A, Hocke M, Selbach J, et al. Papillary renalcell carcinoma in the transplanted kidney-a case reportfocusing on contrast enhanced ultrasound features [J].Med Ultrason,2012,14 : 246 — 250.
  • 4Jung S C, Cho J Y, Kim S H. Subtype differentiationof small renal cell carcinomas on three-phase MDCT :usefulness of the measurement of degree and heteroge-neity of enhancement[J]. Acta Radiol,2012,53: 112- 118.
  • 5KimK H,You D,Jeong I G,et al. Type II papillaryhistology predicts poor outcome in patients with renalcell carcinoma and vena cava thrombus [J]. BJU Int,2012,110: E673-E678.
  • 6Pichler M,Hutterer G C, Chromecki T F, et al. Pres-ence and extent of histological tumour necrosis is an ad-verse prognostic factor in papillary type 1 but not in pa-pillary type 2 renal cell carcinoma[J]. Histopathology,2013’ 62: 219-228.

二级参考文献7

  • 1方祖军,燕翔,郑捷,杨醌,陈波,姚孟树,丁强,张元芳.肾癌的病理类型与预后的关系[J].临床泌尿外科杂志,2006,21(4):262-263. 被引量:22
  • 2周瑞锦,宋少康,姬彤宇.乳头状肾细胞癌的临床病理研究[J].医药论坛杂志,2007,28(2):11-12. 被引量:2
  • 3Novara G,Martignoni G,Artibani W,et al. Grading systems in renal cell carcinoma[J]. J Urol, 2007,177(2):430.
  • 4张长淮.成人肾肿瘤.见:夏同礼主编.现代泌尿病理学[M].北京:人民卫生出版,2002:109-110.
  • 5Giberti C, Oneto F, Martorana G, et al.Radical nephrectomy for renal cell carcinoma:longterm results and prognosticfactors on series of 328 cases[J].Eur Uro1,1997,31(2) :40.
  • 6Garcia JA, Rini BI. Recent progress in the management of advanced renal cell carcinoma[J].Cancer J Clin,2007,57(2):112.
  • 7马建辉.借鉴国际研究进展 提高肾癌诊治水平[J].中华泌尿外科杂志,2003,24(4):221-222. 被引量:7

共引文献6

同被引文献17

  • 1Harshman LC,Yu RJ,Allen GI,et al. Surgical outcomes and compli - cations associated with presurglcal tyrosine kinase inhibition for advanced renal cell carcinoma (RCC) [J]. Urol. Oncol, 2013,31: 379-385.18.
  • 2Guo J, Huang YR,Zhang X,et al.Safety and efficacy of everolimus in Chinese patients with metastatic renal cell carcinoma resistant to vascular endothelial growth factor receptor-tyrosine kinase inhibitor therapy:an open-label phase lb study[J]. BMC Cancer,2013,13:136.
  • 3National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: kidney cancer.2013.V1.May 12th,2012.
  • 4Procopio G, Bellmunt J, Dutcher J, et al. Sorafenib tolerability in elderly patients with advanced renal cell carcinoma:results from a large pooled analysis[J].Br J Cancer,2013,108:311-318.
  • 5Bergmann L,Goebell PJ,Kube U,et al.Everolimus in metastatic renal cell carcinoma after failure of initial vascular endothelial growth factor receptor-tyrosine kinase inhibitor (VEGFr-TKI) therapy: results of an interim analysis of a non-interventional study[J]. Oncology,2013,36:95-100.
  • 6吴义生,吴长利,陈剑秋.肾癌伴腔静脉癌栓的手术治疗[J].中国肿瘤临床,2010,37(14):817-819. 被引量:1
  • 7王权,周文生.小肾癌的治疗策略[J].中华全科医学,2010,8(12):1590-1592. 被引量:5
  • 8张志强,于德新,方卫华,江山,施浩强,廖贵益,赵磊.年龄和环境对肾细胞癌临床病理特征的影响[J].实用癌症杂志,2010,25(6):642-645. 被引量:1
  • 9韩精超,纪志刚,李汉忠.肾部分切除术治疗肾肿瘤的安全性及疗效分析[J].中华泌尿外科杂志,2011,32(5):303-306. 被引量:37
  • 10程洋生,周盛川,符建.腹膜后腹腔镜下肾切除术临床应用体会[J].中国伤残医学,2011,19(4):15-16. 被引量:1

引证文献1

二级引证文献3

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部